Novavax, Inc.’s proposed COVID-19 vaccine showed strong efficacy against older variants, but the US Food and Drug Administration now wonders how it will perform against the current virus strain.
The company is seeking an emergency use authorization for a two-dose primary series of its adjuvanted recombinant spike protein nanoparticle...







